Mabpharm Limited

HK$0.48As of Sun 8 Nov 2026, 12:00 UTC
HKEX:2181Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 7Y CAGR (11.68%)
Div yield —
ROE 58.49%
Biotechnology
Beta (5Y) 0.51
PE TTM 21.55
TSR TTM (7.69%)
Mkt cap HK$1.980B
ROIC 4.95%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.572
19.22%
(87.18%)
Hold 6|12|6|7|0
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.01
0.01
0.01
0.01
(10.27%)
(5.94%)
(4.10%)
1.35%
Revenue¥M
96.47
101.6
101.1
105.6
0.53%
5.21%
1.12%
7.12%
Peers (US$249.9M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
1.898
(0.219)
(0.213)
EBIT/Intx
2.233
0.049
0.060
Own earn%
464.84
(175.92)
(139.26)
Sh yield%
15.41
54.55
56.82
Owners
Insiders/Inst%
12.98
63.95
Short interest%
0.57
SBC / revenue%
3.32
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
23
Op margin range%
9–17
$1 testx
−5.1
Incr. ROIC%
3